Cognition Therapeutics, Inc. Common Stock (CGTX) Stock Price

CGTXStock
$1.0364.96%52W
Market Cap$97.95M
P/E
PEG Ratio
Div yield
Beta1.84

CGTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.48%
Price vs S&P 500 (4W)3.55%
VGM Score27.42

CGTX Earnings Surprise History

Q2 25-0.11est. -0.10
Q3 25-0.06est. -0.09
Q4 25-0.02est. -0.08
Q1 26-0.05est. -0.07
Q2 26-0.04est. -0.06

CGTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.10
4.11

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CGTXCognition Therapeutics, Inc. Common Stock
D$1.03
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Cognition Therapeutics, Inc. Common Stock

Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for age-related degenerative diseases of the central nervous system and retina. Its lead candidate, CT1812, is an oral antagonist designed to cross the blood-brain barrier and selectively bind to the S2R complex. The company is advancing this approach through clinical development.